Shares Savient Pharmaceuticals Inc (NASDAQ: SVNT) are spiking this morning on renewed takeover speculation. The stock opened up slightly trading fairly flat until volume came in around the 12.55 level pushing the stock up to 12.81 on...(
read more)
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its previously announced process to identify, following the approval of KRYSTEXXA™ by the U.S. Food and Drug Administration, a strategic transaction for the sale of the...(
read more)
Strike this one up on the winners side of the FDA crap shoot board! Savient's gout drug,
Krystexxa; which was denied last year, has been approved by the FDA this evening. SVNT's shares are...(
read more)